Results 91 to 100 of about 9,061 (176)

Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study

npj Breast Cancer
In monarchE, adjuvant abemaciclib significantly improved invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS), with sustained benefit beyond the 2-year treatment period.
Matthew P. Goetz, Irfan Cicin, Laura Testa, Sara M. Tolaney, Jens Huober, Valentina Guarneri, Stephen R. D. Johnston, Miguel Martin, Priya Rastogi, Nadia Harbeck, Ashwin Shahir, Ran Wei, Valérie André, Hope S. Rugo, Joyce O’Shaughnessy   +14 more
doaj   +1 more source

Abemaciclib-associated psychosis: a case report of a rare neuropsychiatric adverse effect during breast cancer treatment

Case Reports in Oncology
Background: Abemaciclib is a cyclin-dependent kinase 4/6 inhibitor widely used in combination with endocrine therapy for the treatment of hormone receptor-positive, HER2-negative advanced and early breast cancer. While generally well-tolerated,
Alexander Chih-Chieh Chang, Elizabeth Hale, Julia Foldi   +2 more
doaj   +1 more source

Omission of sentinel lymph node biopsy in early stage luminal breast cancer: impact on adjuvant CDK4/6 inhibitor recommendation and oncological outcomes

Breast
Background: Sentinel lymph node biopsy (SLNB) omission is safe in many patients with small, clinically and imaging node-negative (cN0/iN0), hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC ...
Martin Heidinger, Tibor A. Zwimpfer, Florian S. Halbeisen, Nadia Maggi, Marie Louise Frevert, Rama Kiblawi, Julie M. Loesch, Fabienne D. Schwab, Christian Kurzeder, Giacomo Montagna, Walter P. Weber   +10 more
doaj   +1 more source

Synergistic Enhancement of Antitumor Effects by Combining Abemaciclib with Desipramine

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, including abemaciclib, have been approved for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced, and metastatic breast cancer.
Sung-Ho Goh, Yongdoo Choi, Young Eun Choi, Yeojin Sung, Yan Li   +4 more
core   +1 more source

Therapeutic Prospects of Abemaciclib for Patients with Endometrial Cancer

Endometrial cancer (EC) is a common gynecologic malignancy with a rising incidence due to obesity, comorbid conditions, and related lifestyle factors.
Ahmad Awada, Sarfraz Ahmad
core   +1 more source

Improved process for the preparation of Abemaciclib [PDF]

The present publication relates to process for the purification of Abemaciclib, chemically known as N-[5-[(4-ethyl-l-piperazinyl) methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-2-pyrimidinamineof Formula ...
Anonymous,
core   +1 more source

Abemaciclib treatment patterns and outcome in HR+/HER2- locally advanced or metastatic breast cancer: a real-world study from Kuwait and Lebanon

Frontiers in Oncology
PurposeThe burden of breast cancer is still growing in the Middle East and North Africa (MENA). BC patients typically present with more advanced stages than in Western countries. Limited information is available regarding the safety and efficacy of novel
Anwar Al Nouri, Faisal Al Terkait, Nagi El Saghir, Hady Ghanem, Joseph Kattan, Cynthia Bishouti, Jade Dreyer, Soniya Rai, Alexandru Rosca   +8 more
doaj   +1 more source

Selective but not pan-CDK inhibition abrogates 5-FU-driven tissue factor upregulation in colon cancer

Scientific Reports
Thromboembolic events are complications in cancer patients and hypercoagulability has been linked to the tissue factor (TF) pathway, making this an attractive target.
Annika Kayser, Annabell Wolff, Peggy Berlin, Lara Duehring, Larissa Henze, Ralf Mundkowski, Wendy Bergmann, Brigitte Müller-Hilke, Charlotte Wagner, Maja Huehns, Sonja Oehmcke-Hecht, Claudia Maletzki   +11 more
doaj   +1 more source

Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2‐ metastatic breast cancer: A single center real‐world study in China

Cancer Medicine
Background Cyclin‐dependent kinase (CDK) 4/6 inhibitor plus endocrine therapy (ET) become standard‐of‐care for patients with hormone receptor‐positive, human epidermal growth factor receptor‐2 negative (HR+/HER2−) metastatic breast cancer (MBC). However,
Hanfang Jiang, Jianxin Zhong, Jing Wang, Guohong Song, Lijun Di, Bin Shao, Ruyan Zhang, Yaxin Liu, Anjie Zhu, Nan Wang, Huiping Li   +10 more
doaj   +1 more source

Improved process for the purification of Abemaciclib [PDF]

The present publication relates to process for the purification of Abemaciclib, chemically known as N-[5-[(4-ethyl-l-piperazinyl) methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1- methylethyl)-1H-benzimidazol-6-yl]-2-pyrimidinamineof Formula ...
Anonymous,
core   +1 more source